pharma focus europe

Greening the Pill: Pharmaceutical Companies Embrace Environmental Sustainability

Health23 days ago

Source: Greening the Pill: Pharmaceutical Companies Embrace Environmental Sustainability

In an age where global environmental sustainability is imperative, various industries are reassessing their practices to diminish their ecological impact. The pharmaceutical sector, a crucial component of healthcare, is no different. This article explores the proactive steps taken by pharmaceutical companies to incorporate sustainability into manufacturing, packaging, and operations, to lessen their environmental footprint.

Bioprocessing Evolution Technology and Trends Transforming Pharma

Health1 months ago

Source: Bioprocessing Evolution Technology and Trends Transforming Pharma

The pharmaceutical bioprocessing industry develops due to progress in technology, increases the demand for biologics, and meets the need for more efficient and adaptable production methods. These changes change biopharmaceutical production, make processes more effective, reduce costs, and accelerate the availability of essential medicines.

Harnessing the Potential of mRNA Technology for Precision Cancer Treatment

Health2 months ago

Source: Harnessing the Potential of mRNA Technology for Precision Cancer Treatment

Approximately 11 months after the viral sequence was published, two mRNA-based SARS-CoV-2 vaccines received emergency approval, demonstrating the potential of the technology. Vaccines for cancer and infectious diseases have proven effective thanks to low dosages, local delivery, and controlled protein expression. Recent advances have been made in cancer, Epstein-Barr virus, HIV, influenza, and Omicron-specific boosters as part of ongoing studies on mRNA-encoded proteins

Fostering Pharma Collaboration: Challenges & Opportunities

Health3 months ago

Source: Fostering Pharma Collaboration: Challenges & Opportunities

Fostering collaboration in the pharmaceutical industry is vital for innovation, yet challenges like regulatory hurdles, intellectual property concerns, and organizational barriers persist. Overcoming these obstacles requires clear goals, trust-building, a collaborative culture, technology investment, and embracing diversity. Leveraging opportunities like technology advancements and public-private partnerships can lead to accelerated drug development and improved patient outcomes.